ARCHIVES

ODAC Rejects Amsacrine NDA, Renews Idarubicin

This article is from The Cancer Letter archive.

Vol. 16 No. 35 | September 14, 1990

Download PDF Visit The Full Archive

Related Articles

Breast Cancer Treatment Studies Need Standard Definitions – Carbone

May 10, 1974

Revlimid Plus Steroid Effective In Clinical Trial

November 30, 2007

NCI Hits Grant Targets, But Labs Feel The Pain Of Budget Cuts, Director Says.

November 23, 2007

ODAC Votes 13:0 to Recommend Perjeta for Accelerated Approval

September 13, 2013

Hutchinson Center Receives NCI Grant For Immunotherapy Network

October 15, 2010

Hormonal Therapy Improves Prostate Cancer Survival

August 27, 2004